Replication-selective adenoviruses as oncolytic agents

Journal of Clinical Investigation

Volumn 105, Issue 7, 2000, Pages 847-851

  Heise, Carla ^a   Kirn, David H ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; ONYX 015; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL KILLING; DRUG TOLERABILITY; GENE DELETION; GENE LOSS; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

EID: 0034077666     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9762     Document Type: Review

References (35)

1. Whyte, P., Williamson, N., and Harlow, E. 1989. Cellular targets for transformation by the adenovirus E1A proteins. Cell. 56:67-75.
2. Barker, D.D., and Berk, A.J. 1987. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 156:107-121.
3. Gomez-Manzano, C., et al. 1996. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56:694-699.
4. Roth, J., and Cristiano, R.J. 1997. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89:21-39.
5. Merritt, J., et al. 1997. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer. Cancer Gene Ther. 4:S12. (Abst.)
6. Smith, R., Huebner, K.J., Rowe, W.P., Schatten, W.E., and Thomas, L.B. 1956. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 9:1211-1218.
7. Kirn, D.H. 1996. Replicating oncolytic viruses: an overview. Expert Opinion on Investigational Drugs. 5:753-762.
8. Heise, C., Williams, A., Xue, S., Propst, M., and Kirn, D. 1999. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59:2623-2628.
9. Kirn, D.H., and McCormick, F. 1996. Replicating viruses as selective cancer therapeutics. Mol. Med. Today. 2:519-527.
10. Day, D.B., Zachariades, N.A., and Gooding, L.R. 1994. Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. Cell Immunol. 157:223-238.
11. Gooding, L.R. 1994. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect. Agents Dis. 3:106-115.
12. Shisler, J., Duerksen, H.P., Hermiston, T.M., Wold, W.S., and Gooding, L.R. 1996. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol. 70:68-77.
13. Kirn, D. 1999. Selectively-replicating viuses as therapeutic agents against cancer. In: Cancer Gene Therapy E. Lattime and S. Gerson, eds.,. Academic Press, San Diego, CA. 235-248
14. Dimitrov, T., et al. 1997. Adenovirus E3- 10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Viorl. 71:2830-2837.
15. Hermiston, T.W., Tripp, R.A., Sparer, T., Gooding, L.R., and Wold, W.S. 1993. Deletion mutation analysis of the adenovirus type 2 E3-gp 19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67:5289-5298.
16. Tollefson, A.E., Ryerse, J.S., Scaria, A., Hermiston, T.W., and Wold, W.S. 1996. The E3-116-kDa adenovirus death protein (ADP) is required for efficient cell death characterization of cells infected with adp mutants. Virology. 220:152-162.
17. Branton, P. 1999. Early gene expression. In Adenoviruses: basic biology to gene therapy. P. Seth, editor. R.G. Landes, Austin, TX. 39-58.
18. Gooding, L.R. 1994. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agent Dis. 3:106-115.
19. Heise, C., Williams, A., Olesch, J., and Kirn, D. 1999. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6:499-504.
20. Ganly, I., et al. 1997. A phase I clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumoral injection in patients with recurrent head and neck cancer. Clin. Cancer Res. (In press).
21. Whyte, P., Ruley, H., and Harlow, E. 1988. Two regions of the adenovirus early region 1A proteins are required for transformation. J. Virol. 62:257-265.
22. Rodriguez, R., et al. 1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Canncer Res. 57:2559-2563.
23. Sherr, C.J. 1996. Cancer cell cycles. Science. 274:1672-1677.
24. Olson, D.C., and Levine, A.J. 1994. The properties of p53 proteins selected for the loss of suppression of transformation. Cell Growth Differ. 5:61-71.
25. Hoise, C., et al. 1997. ONYX-015, and E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:639-645.
26. Kirn, D., Heise, C., Williams, M., Propst, M., and Hermiston, T. 1998. Adenovirus E1A CR2 mutants as selectively-replicating agents for cancer. Presented at Cancer Gene Therapy, meeting(R. Sobol and K. Scanlon, organizers). San Deigo, Ca.
27. Bischoff, J.R., et. al. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373-376.
28. Heise, C., et al. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Natl. Med. 3:639-645.
29. Goodrum, F.D., and Ornelles, D.A. 1997. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71:548-561.
30. Hall, A.R. Dix, B.R., O'Carroll, S.J., and Braitluwaite, A.W. 1998. p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]. Nat. Med. 4:1068-1072.
31. Turnell, A.S., Grand, R.J., and Gallimore, P.H. 1999. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell P53 status. J. Virol. 73:2074-2083.
32. Rothmann, T., Hengstermann, A., Whitaker, N.J., Scheffner, M., and zur Hausen, H. 1998. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:9470-9478.
33. Kirn, D., et al. 1998. A phase II trial of intratumoral injection with an E1B-deleted adenovirus. ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 17:391a. (Abst.)
34. Kirn, D., Hermiston, T., and McCormick, F. 1998. ONVX-015: clinical data are encouraging. Nat. Med. 4:1341-1342.
35. Kirn, D.H., et al. 1999. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. 18:1505.